Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, was submitted on May 6, 2026. The report serves to distribute a press release dated May 6, 2026, to U.S. investors. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a cover sheet referencing an external press release (Exhibit 99.1) and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the formal submission of a press release, the details of which are not included in the source text.
Key Facts for Investor Verification
- Verify the content of the referenced Press Release (Exhibit 99.1) dated May 6, 2026, for specific operational or financial updates.
- Confirm the identity of the signatory, Jonathan Dickinson, as the Chief Executive Officer.
- Note that this filing is a procedural submission under Rule 13a-16 and does not contain standalone financial data.